Aruba vs Saint Kitts and Nevis: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Aruba
0.2%
in 2024
Saint Kitts and Nevis
0.2%
in 2024
Aruba rank
98th
Saint Kitts and Nevis rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Aruba
- Saint Kitts and Nevis
How they compare
Aruba currently reports 0.2% against 0.2% in Saint Kitts and Nevis, a difference of 0.0%.
Across all 10 years both countries report, Saint Kitts and Nevis has been ahead every year.
Aruba ranks 98th and Saint Kitts and Nevis ranks 98th of 246 countries.
Head to head by decade
| Decade | Aruba | Saint Kitts and Nevis | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Aruba or Saint Kitts and Nevis?
- Aruba, at 0.2% against 0.2% in Saint Kitts and Nevis as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Aruba and Saint Kitts and Nevis?
- 0.0%, with Aruba ahead.
- How many years of comparable data are there for Aruba and Saint Kitts and Nevis?
- 10 years are reported by both, from 2015 to 2024.
- How do Aruba and Saint Kitts and Nevis rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Aruba ranks 98th and Saint Kitts and Nevis ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.